Immunotherapy & TACE in HCC Treatment
with Dr. Julius Chapiro and Dr. Richard Finn
There are now multiple phase 3 studies on combination transarterial
chemoembolization (TACE) and immunotherapy showing a significant benefit
over TACE alone. How do these findings change the hepatocellular
carcinoma (HCC) treatment algorithm? In this multidisciplinary episode
of the BackTable Podcast, Dr. Richard Finn (Medical Oncologist at UCLA)
and Dr. Julius Chapiro (Interventional Radiologist at Yale University)
join host Dr. Chris Beck to discuss immunotherapy, TACE, emerging trends
in HCC treatment, and the future of the field.